1089 related articles for article (PubMed ID: 25372357)
21. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre.
Thong KM; Ong AC
QJM; 2013 Jul; 106(7):639-46. PubMed ID: 23587574
[TBL] [Abstract][Full Text] [Related]
22. Hospital resource utilization that occurs with, rather than because of, kidney failure in patients with end-stage renal disease.
Ross EA; Alza RE; Jadeja NN
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1234-40. PubMed ID: 17699353
[TBL] [Abstract][Full Text] [Related]
23. Management of ESRD in patients with autosomal dominant polycystic kidney disease.
Alam A; Perrone RD
Adv Chronic Kidney Dis; 2010 Mar; 17(2):164-72. PubMed ID: 20219619
[TBL] [Abstract][Full Text] [Related]
24. Inpatient economic and mortality assessment for liver transplantation: a nationwide study of the United States data from 2005 to 2009.
Wai H; Stepanova M; Saab S; Erario M; Srishord M; Younossi ZM
Transplantation; 2014 Jan; 97(1):98-103. PubMed ID: 24056627
[TBL] [Abstract][Full Text] [Related]
25. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation.
de Mattos AM; Olyaei AJ; Prather JC; Golconda MS; Barry JM; Norman DJ
Kidney Int; 2005 Feb; 67(2):714-20. PubMed ID: 15673321
[TBL] [Abstract][Full Text] [Related]
26. End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases.
Brunelli SM; Blanchette CM; Claxton AJ; Roy D; Rossetti S; Gutierrez B
Clinicoecon Outcomes Res; 2015; 7():65-72. PubMed ID: 25609987
[TBL] [Abstract][Full Text] [Related]
27. Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?
Jankowska M; Qureshi AR; Barany P; Heimburger O; Stenvinkel P; Lindholm B
Nephrology (Carlton); 2018 Jan; 23(1):31-36. PubMed ID: 27653449
[TBL] [Abstract][Full Text] [Related]
28. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
29. All-cause costs increase exponentially with increased chronic kidney disease stage.
Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
[TBL] [Abstract][Full Text] [Related]
30. The societal economic burden of autosomal dominant polycystic kidney disease in the United States.
Cloutier M; Manceur AM; Guerin A; Aigbogun MS; Oberdhan D; Gauthier-Loiselle M
BMC Health Serv Res; 2020 Feb; 20(1):126. PubMed ID: 32070341
[TBL] [Abstract][Full Text] [Related]
31. Comparison of hospitalization outcomes for delivery and resource utilization between pregnant women with kidney transplants and chronic kidney disease in the United States.
Chewcharat A; Kattah AG; Thongprayoon C; Cheungpasitporn W; Boonpheng B; Gonzalez Suarez ML; Craici IM; Garovic VD
Nephrology (Carlton); 2021 Nov; 26(11):879-889. PubMed ID: 34240784
[TBL] [Abstract][Full Text] [Related]
32. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
33. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.
Wu N; Yu YF; Chuang CC; Wang R; Benjamin NN; Coultas DB
J Med Econ; 2015 Apr; 18(4):249-57. PubMed ID: 25428658
[TBL] [Abstract][Full Text] [Related]
34. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years.
Dicks E; Ravani P; Langman D; Davidson WS; Pei Y; Parfrey PS
Clin J Am Soc Nephrol; 2006 Jul; 1(4):710-7. PubMed ID: 17699277
[TBL] [Abstract][Full Text] [Related]
35. Clinical burden of autosomal dominant polycystic kidney disease.
Hung PH; Lin CH; Hung KY; Muo CH; Chung MC; Chang CH; Chung CJ
Aging (Albany NY); 2020 Feb; 12(4):3899-3910. PubMed ID: 32096480
[TBL] [Abstract][Full Text] [Related]
36. Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis.
Deitelzweig S; Amin A; Christian R; Friend K; Lin J; Lowe TJ
Adv Ther; 2013 Jan; 30(1):71-80. PubMed ID: 23292659
[TBL] [Abstract][Full Text] [Related]
37. Insurance for autosomal dominant polycystic kidney disease patients prior to end-stage renal disease.
Golin CO; Johnson AM; Fick G; Gabow PA
Am J Kidney Dis; 1996 Feb; 27(2):220-3. PubMed ID: 8659497
[TBL] [Abstract][Full Text] [Related]
38. Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group.
Christophe JL; van Ypersele de Strihou C; Pirson Y
Nephrol Dial Transplant; 1996 Jul; 11(7):1271-6. PubMed ID: 8672022
[TBL] [Abstract][Full Text] [Related]
39. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
[TBL] [Abstract][Full Text] [Related]
40. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
